financetom
Business
financetom
/
Business
/
What's Going On With VSE Corp Stock Today?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With VSE Corp Stock Today?
Feb 18, 2025 11:25 AM

VSE Corporation ( VSEC ) shares rose on Tuesday following the announcement of a definitive agreement to sell its Fleet business segment, Wheeler Fleet Solutions, to One Equity Partners for up to $230 million.

Wheeler Fleet Solutions is a parts distributor and engineering solutions provider servicing the medium and heavy-duty fleet market.

Wheeler Fleet Solutions employs approximately 385 people across three primary distribution centers in Pennsylvania, Mississippi and Texas.

The transaction is part of VSE’s strategic transformation, aimed at simplifying the business and focusing on its core business — aviation aftermarket services, according to a press release.

Also Read: Kim Kardashian’s SKIMS Joins Forces With Nike For Fitness Fashion, Stock Gains

John Cuomo, President and CEO of VSE, expressed that the divestiture is the final step in the company’s portfolio transformation, which will enhance its global leadership position in the aviation aftermarket parts and services market.

The sale includes a $140 million cash payment at closing, a $25 million seller note, and up to $65 million in contingent earnout consideration.

The deal is expected to close in the second quarter of 2025, subject to customary closing conditions.

According to Benzinga Pro, VSEC stock has gained over 41% in the past year. Investors can gain exposure to the stock via iShares Microcap ETF .

Price Action: VSEC shares are trading higher by 1.99% to $99.22 at last check Tuesday.

Read Next:

Why Intel, Airbnb, Joby Aviation Are Among JPMorgan’s Short Ideas

Image sourced from Shutterstock.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Greenwich Lifesciences Insider Bought Shares Worth $380,945, According to a Recent SEC Filing
Greenwich Lifesciences Insider Bought Shares Worth $380,945, According to a Recent SEC Filing
Mar 7, 2024
06:52 AM EST, 03/07/2024 (MT Newswires) -- Snehal Patel, 10% Owner, Director, CEO and CFO, on March 05, 2024, executed a purchase for 30,500 shares in Greenwich Lifesciences ( GLSI ) for $380,945. Following the Form 4 filing with the SEC, Patel has control over a total of 5,343,777 shares of the company, with 5,343,777 shares held directly. SEC Filing:...
Cigna launches program to help clients manage rising costs due to weight loss drug boom
Cigna launches program to help clients manage rising costs due to weight loss drug boom
Mar 7, 2024
March 7 (Reuters) - Cigna ( CI ) on Thursday announced its unit is launching a financial guarantee program to help companies and other clients manage the rising drugs expenses associated with using GLP-1 weight loss and diabetes drugs. ...
Nvidia Insider Sold Shares Worth $170,020,366, According to a Recent SEC Filing
Nvidia Insider Sold Shares Worth $170,020,366, According to a Recent SEC Filing
Mar 7, 2024
06:48 AM EST, 03/07/2024 (MT Newswires) -- Tench Coxe, Director, on March 05, 2024, sold 200,000 shares in Nvidia ( NVDA ) for $170,020,366. Following the Form 4 filing with the SEC, Coxe has control over a total of 3,787,612 shares of the company, with 5,228 shares held directly and 3,782,384 shares controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1045810/000122520824003814/xslF345X03/doc4.xml ...
GSK Reports Positive Results From Interim Analysis of Test of Potential Blood Cancer Treatment -- Shares Up Pre-Bell
GSK Reports Positive Results From Interim Analysis of Test of Potential Blood Cancer Treatment -- Shares Up Pre-Bell
Mar 7, 2024
06:51 AM EST, 03/07/2024 (MT Newswires) -- GSK (GSK) said Thursday that it had received positive results from an interim analysis of a late-stage study of its potential multiple myeloma treatment Blenrep in combination with pomalidomide plus dexamethasone compared with bortezomib plus dexamethasone. The company said the trial, involving 302 patients, met its primary endpoint of progression-free survival at a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved